Catherine, are you sure that you have posted the right link?
The title of the study in the link is “A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)” and the intervention only mentions Nivolumab.
You are correct EvaSara, I apologize. I meant to post this one: https://clinicaltrials.gov/show/NCT02186249 but now I am trying to make sure it is available globally. This is the combo of IPI/PD1. The other is just PD1 for those who have progressed on IPI. Sorry for any confusion I may have caused.
I’m still double checking with Bristol Myers Squibb and perhaps there is a plan in place to have it. In the meantime I did hear from UZ/Brussel: both nivolumab and pembrolizumab therapy available in our center (UZ Brussel, Brussels, Belgium), (post ipilimumab treatment).